Tanrıkulu Bahattin, Danyeli Ayça Erşen, Özek M Memet
Department of Neurosurgery, Division of Pediatric Neurosurgery, Acıbadem University School of Medicine, Istanbul, Turkey.
Department of Pathology, Acıbadem University School of Medicine, Istanbul, Turkey.
Childs Nerv Syst. 2020 May;36(5):941-949. doi: 10.1007/s00381-020-04518-5. Epub 2020 Feb 5.
Posterior fossa ependymomas (PFE) are among the most frequently occurring solid tumors in children. Their definitive treatment is surgical excision and adjuvant radio-chemotherapy. This study aimed to investigate prognostic effects of age, H3K27me3 status, extent of resection, radiation treatment (RT), Ki67 index, WHO grade, and ATRX and H3K27M mutations in PFE patients.
This retrospective study included 42 pediatric patients with PFE who had undergone operation at our institution between 1996 and 2018. Patient demographics and treatment information were obtained from patient notes. Information on radiological location of tumors (median vs paramedian), extent of tumor resection, and recurrence was obtained from preoperative and postoperative magnetic resonance imaging. Formalin-fixed paraffin-embedded tumor samples were evaluated for H3K27me3 immunostaining, Ki67 index, WHO grades, and ATRX and H3K27M mutations. Tumor samples with global reduction in H3K27me3 were grouped as posterior fossa ependymoma group A (PFA) and those with H3K27me3 nuclear immunopositivity as posterior fossa ependymoma group B (PFB). We evaluated the cohort's 5-year progression-free survival (PFS) and overall survival (OS).
There were 20 (47.6%) female and 22 (52.4%) male patients in the cohort. The mean age of patients was 4.4 (range, 0.71-14.51) years. Overall, tumors in 31 (73.8%) and 11 (26.2%) patients were found to be PFA and PFB, respectively. There was no statistically significant age or sex difference between PFA and PFB. All patients received chemotherapy, whereas only 28 (66.6%) received RT. The WHO grades of PFA were statistically higher than those of PFB. There was no significant difference between PFA and PFB in terms of extent of resection, disease recurrence, and survival parameters. Nine of 42 tumor samples had ATRX mutations. One patient with PFA showed H3K27M mutation. Age, WHO grade, H3K27me3 status, and RT had no effect on patients' PFS and OS. Patients with total surgical excisions had significantly better PFS and OS rates. Those with Ki67 < 50% also had better OS rates.
Determining H3K27me3 status by immunohistochemistry is a widely accepted method for molecular subgrouping of PFEs. Most of the reports in the literature state that molecular subgroups of PFEs have significantly different clinical outcomes. However, in our present series, we have shown that the extent of surgical excision is still the most important prognostic indicator in PFEs. We also conclude that the prognostic effect of H3K27me3 status-based molecular subgrouping may be minimized with a more aggressive surgical strategy followed in PFAs.
后颅窝室管膜瘤(PFE)是儿童中最常见的实体瘤之一。其明确的治疗方法是手术切除和辅助放化疗。本研究旨在探讨年龄、H3K27me3状态、切除范围、放射治疗(RT)、Ki67指数、世界卫生组织(WHO)分级以及PFE患者中ATRX和H3K27M突变的预后影响。
这项回顾性研究纳入了1996年至2018年间在本机构接受手术的42例儿童PFE患者。患者人口统计学和治疗信息来自患者病历。肿瘤的放射学位置(中线与旁中线)、肿瘤切除范围和复发信息来自术前和术后的磁共振成像。对福尔马林固定石蜡包埋的肿瘤样本进行H3K27me3免疫染色、Ki67指数、WHO分级以及ATRX和H3K27M突变评估。H3K27me3整体减少的肿瘤样本归为后颅窝室管膜瘤A组(PFA),H3K27me3核免疫阳性的样本归为后颅窝室管膜瘤B组(PFB)。我们评估了该队列的5年无进展生存期(PFS)和总生存期(OS)。
该队列中有20例(47.6%)女性和22例(52.4%)男性患者。患者的平均年龄为4.4岁(范围0.71 - 14.51岁)。总体而言,分别在31例(73.8%)和11例(26.2%)患者中发现肿瘤为PFA和PFB。PFA和PFB之间在年龄或性别上无统计学显著差异。所有患者均接受了化疗,而仅28例(66.6%)接受了RT。PFA的WHO分级在统计学上高于PFB。PFA和PFB在切除范围、疾病复发和生存参数方面无显著差异。42个肿瘤样本中有9个存在ATRX突变。1例PFA患者显示H3K27M突变。年龄、WHO分级、H3K27me3状态和RT对患者的PFS和OS无影响。手术全切的患者PFS和OS率显著更好。Ki67<50%的患者OS率也更好。
通过免疫组织化学确定H3K27me3状态是PFE分子亚组分类的一种广泛接受的方法。文献中的大多数报告指出,PFE的分子亚组具有显著不同的临床结果。然而,在我们目前的系列研究中,我们表明手术切除范围仍然是PFE中最重要的预后指标。我们还得出结论,对于PFA采用更积极的手术策略,基于H3K27me3状态的分子亚组分类的预后影响可能会最小化。